| Autor: |
Johnston KM; ICON Epidemiology, Vancouver, BC, Canada., McPherson E, Osenenko K, Vergidis J, Levy AR, Peacock S |
| Jazyk: |
angličtina |
| Zdroj: |
Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2015 Apr; Vol. 15 (2), pp. 229-42. Date of Electronic Publication: 2015 Feb 23. |
| DOI: |
10.1586/14737167.2015.1017563 |
| Abstrakt: |
Melanoma presents an important burden worldwide. Until recently, the prognosis for unresectable and metastatic melanoma was poor, with 10% of metastatic melanoma patients surviving for 2 years. The introduction of newer therapies including ipilimumab, vemurafenib, dabrafenib and trametinib improved progression-free survival, with additional benefits anticipated from the forthcoming class of programmed cell death 1 inhibitors. Cost of therapy and resulting cost-effectiveness is an important factor in determining patient access to specific treatments. The objective of this study was to review the published evidence regarding cost-effectiveness of melanoma therapies and provide an overview of the relative cost-effectiveness of available therapies by disease stage. For earlier-stage disease, IFN-α has been found to be cost-effective, although its clinical benefits have not been well established. For unresectable and metastatic melanoma, newer therapies provide benefits over standard-of-care chemotherapy, but comprehensive analyses will need to be conducted to determine the most cost-effective therapy. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
